Literature DB >> 10965830

Tissue gas tensions in patients with necrotising fasciitis and healthy controls during treatment with hyperbaric oxygen: a clinical study.

K Korhonen1, K Kuttila, J Niinikoski.   

Abstract

OBJECTIVE: To investigate the effect of hyperbaric oxygen (HBO) treatment on tissue oxygen and carbon dioxide tensions in patients with necrotising fasciitis and healthy volunteers.
DESIGN: Clinical study in patients and healthy controls.
SETTING: University hospital, Finland.
SUBJECTS: 6 patients with necrotising fasciitis and 3 healthy volunteers.
INTERVENTIONS: Subcutaneous tissue PO2 and PCO2 tensions were measured directly in patients with necrotising fasciitis and in healthy volunteers during normobaric and hyperbaric conditions. Arterial blood PO2 and PCO2 tensions were measured only in the patients. Tissue gas tensions were measured with a Silastic tube tonometer implanted in the brachial subcutaneous tissue of both patients and controls as well as in the subcutaneous tissue of the patients in the immediate vicinity of the necrotising process. The diagnosis of necrotising fasciitis was made on the basis of the presence of typical clinical signs and symptoms, intraoperative findings, and microbiological observations. MAIN OUTCOME MEASURES: Arterial and subcutaneous tissue PO2 and PCO2 tensions.
RESULTS: In patients with necrotising fasciitis the arterial PO2 rose about 7-fold whereas the arterial PCO2 increased only slightly during exposure to 2.5 absolute atmospheres (ATA) of oxygen. During HBO the subcutaneous tissue PO2 increased four to five fold from the baseline and CO2 tensions also increased, but to a lesser degree, in both healthy and infected tissues. In patients with necrotising fasciitis, the PO2 was higher, but not significantly so, in the vicinity of the infected area than in the healthy tissue.
CONCLUSION: Under hyperbaric conditions the subcutaneous PO2 in patients with necrotising fasciitis rose higher in the vicinity of the infected area than in the healthy tissue, which may be the result of vasodilatation and increased microcirculation induced by the inflammatory process associated with infection or it may be the result of decreased local tissue oxygen utilisation, or both. The tissue PCO2 values tended to rise during HBO probably from hypoventilation or reduced CO2 washout from tissue because venous blood haemoglobin was fully saturated with oxygen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965830     DOI: 10.1080/110241500750008583

Source DB:  PubMed          Journal:  Eur J Surg        ISSN: 1102-4151


  6 in total

Review 1.  Adjunctive hyperbaric oxygen for necrotizing fasciitis.

Authors:  Denny Levett; Michael H Bennett; Ian Millar
Journal:  Cochrane Database Syst Rev       Date:  2015-01-15

2.  Tadalafil therapy and severe chronic foot wound resolution.

Authors:  Claire Davenport; Andrew Dubin
Journal:  Int Wound J       Date:  2015-02-03       Impact factor: 3.315

Review 3.  Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes.

Authors:  Timo W Hakkarainen; Nicole M Kopari; Tam N Pham; Heather L Evans
Journal:  Curr Probl Surg       Date:  2014-06-12       Impact factor: 1.909

4.  Necrotizing fasciitis of the neck and head complicated with chronic osteomyelitis: Case report presentation.

Authors:  Rosa María Wong-Chew; Antonio H Angel-Ambrocio; Sheila Yadira Gomez-Murillo; Angel Puente-Sanchez; Gerardo Fernandez-Sobrino; Alfonso Marhx-Bracho; María de Lourdes Marroquín-Yañez
Journal:  Int J Surg Case Rep       Date:  2019-03-26

5.  Hyperbaric oxygen treatment is associated with a decrease in cytokine levels in patients with necrotizing soft-tissue infection.

Authors:  Morten Hedetoft; Peter Garred; Martin Bruun Madsen; Ole Hyldegaard
Journal:  Physiol Rep       Date:  2021-03

6.  Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection.

Authors:  Morten Hedetoft; Peter Østrup Jensen; Claus Moser; Julie Vinkel; Ole Hyldegaard
Journal:  J Investig Med       Date:  2021-05-18       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.